Procedural
OtherAll subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
NCT Number: NCT02626832
This study aims to develop a method for the assessment of central NMDA receptor functioning in patients with depression and schizophrenia. For this purpose a transitional approach is used based on preclinical studies that show a dose-dependent relationship between the activity of hypothalamic NMDA receptor and plasma AVP response to increasing plasma osmolality. Patients with schizophrenia, depression and healthy controls participated in this study. The Investigators found that in a subgroup of patients with schizophrenia the AVP response was low and that in a subgroup of subjects with depression the AVP response was high compared to healthy controls.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Not applicable
The John Pierce Laboratory, New Haven, Connecticut, United States
Evidence suggests that altered N-methyl-D-aspartate (NMDA) receptor activity and glutamate signaling may underlie the pathogenesis of both schizophrenia and depression at least in subgroups of patients. In schizophrenia, pharmacologic modeling, postmortem and imaging data suggest reduced NMDA signaling. In contrast, recent clinical trials demonstrating the efficacy of the NMDA antagonist ketamine in severely depressed patients suggest increased NMDA receptor signaling. The Investigators have conducted a proof of concept study to assess whether there is any in vivo evidence for an inverse association in depression and schizophrenia with respect to the NMDA receptor function. For this purpose the investigators used a translational approach, based on findings from animal studies that NMDA receptor is a key mediator of arginine-vasopressin (AVP) release into the bloodstream. Using hypertonic saline to induce AVP release, as done in animal studies, it was found that in a subgroup of depressed patients, NMDA receptor mediated AVP release was significantly increased, whereas in a subgroup of schizophrenia patients, the same response was abnormally low. Previous research has demonstrated that this response is well conserved. These findings are consistent with implicated NMDA receptor related abnormalities in depression and schizophrenia in subgroups of patients, and provide the first in vivo evidence towards this dichotomy.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for healthy controls:
Exclusion criteria
for healthy controls:
Inclusion criteria
for patients with schizophrenia:
Exclusion criteria
for patients with schizophrenia
Inclusion criteria
for patients with depression:
Exclusion criteria
for patients with depression:
Inclusion criteria
for patients from the PRIME Clinic:
Exclusion criteria
for patients from the PRIME Clinic:
All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
Time frame: Within 3 months
Yale University
Other
Regulation of Arginine-vasopressin (AVP) in Psychiatric Disorders
Acronym: REGAVP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01466439
Behavior, Behavioral Symptoms
Caen, France
View Trial DetailsNCT06038955
Behavior, Behavioral Symptoms
Frederiksberg, Capital Region of Copenhagen, Denmark
View Trial DetailsNCT03451630
Anxiety, Anxiety Disorders
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT02022462
Behavior, Behavioral Symptoms
Santa Fe Springs, California, United States
View Trial Details